VisMederi Takes the Lead in Assessing Safety and Immunogenicity of Yellow Fever Vaccine

May 25, 2023News&events0 comments

Introduction: Yellow fever (YF), a mosquito-borne disease caused by the flavivirus genus of the family Flaviviridae, remains a significant global health concern. With its devastating impact on human populations, the urgent need for effective prevention and control measures cannot be overstated. In the forefront of this battle is VisMederi, a pioneering organization dedicated to clinical studies and diagnostics. VisMederi’s focus on assessing the safety and immunogenicity of the yellow fever vaccine has positioned them at the forefront of combating this formidable disease.

The Challenge of Yellow Fever: Yellow fever is part of a family of viruses that includes several clinically significant pathogens, such as Dengue, Zika, West Nile, and Japanese encephalitis viruses. Annually, yellow fever contributes to approximately 200,000 cases and 30,000 deaths, with Africa bearing the brunt of this burden, accounting for 90% of cases. Despite the existence of a safe and effective vaccine that provides long-lasting immunity, yellow fever remains a major public health problem.

Serological Testing and VisMederi’s Breakthrough: Serological tests have played a crucial role in measuring anti-flaviviral antibodies and evaluating immune responses. Among these tests, the plaque reduction neutralization test (PRNT) stands out as the most virus-specific, providing a direct measurement of in vitro neutralization. This test correlates well with serum levels of protection from virus infection and is considered the gold standard for assessing immunity against flaviviruses.

VisMederi has successfully validated the Yellow Fever PRNT assay, an achievement that holds tremendous significance in the fight against yellow fever. Following the guidelines established by the World Health Organization (WHO), VisMederi’s operational methods adhere to the WHO/IVB/07.07 guidelines for performing the general virus plaque reduction neutralization assay. With a dedicated team conducting PRNT assays daily, VisMederi analyzes multiple samples against the Yellow Fever virus strain 17D.

Advancing Flavivirus Research and Vaccine Development: The flavivirus family represents a new frontier for future studies and the development of vaccines. With VisMederi’s expertise and the availability of the PRNT test, researchers now have a powerful tool to investigate immune responses against various flaviviruses, including yellow fever. This breakthrough opens doors to new avenues of research, enabling a deeper understanding of these diseases and the development of more effective vaccines.

Conclusion: VisMederi’s leading role in the assessment of yellow fever vaccine safety and immunogenicity using the PRNT test underscores their commitment to public health. With yellow fever continuing to pose a significant threat, the validation of the Yellow Fever PRNT assay represents a major stride in the fight against this devastating disease. By enabling precise measurements of immune responses, VisMederi’s groundbreaking work contributes to the development of improved vaccines and a brighter future in the battle against flaviviruses.